Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Evoked Potentials, Auditory, Brain Stem | 7 | 2022 | 8 | 1.850 |
Why?
|
| Auditory Perception | 5 | 2018 | 48 | 1.730 |
Why?
|
| Hearing Loss, Noise-Induced | 3 | 2022 | 6 | 1.690 |
Why?
|
| Anura | 6 | 2021 | 32 | 1.410 |
Why?
|
| Deafness | 4 | 2023 | 7 | 1.350 |
Why?
|
| Auditory Threshold | 5 | 2022 | 7 | 1.080 |
Why?
|
| Hearing Loss | 3 | 2020 | 15 | 1.070 |
Why?
|
| Noise | 4 | 2022 | 9 | 0.930 |
Why?
|
| Vocalization, Animal | 4 | 2017 | 22 | 0.800 |
Why?
|
| HIV Infections | 7 | 2023 | 2303 | 0.790 |
Why?
|
| Cochlear Nucleus | 1 | 2018 | 1 | 0.660 |
Why?
|
| Hyperkinesis | 1 | 2018 | 7 | 0.650 |
Why?
|
| Spiral Ganglion | 1 | 2018 | 5 | 0.650 |
Why?
|
| Diet | 5 | 2023 | 801 | 0.590 |
Why?
|
| Sex Factors | 3 | 2017 | 898 | 0.590 |
Why?
|
| Behavior, Animal | 1 | 2018 | 314 | 0.550 |
Why?
|
| Hearing | 5 | 2023 | 9 | 0.540 |
Why?
|
| Mice, Inbred CBA | 5 | 2022 | 38 | 0.530 |
Why?
|
| Peripheral Nervous System | 1 | 2015 | 11 | 0.510 |
Why?
|
| Acoustic Stimulation | 6 | 2022 | 66 | 0.500 |
Why?
|
| Male | 23 | 2023 | 20025 | 0.480 |
Why?
|
| Body Size | 1 | 2014 | 32 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 643 | 0.460 |
Why?
|
| Physician Assistants | 2 | 2023 | 14 | 0.450 |
Why?
|
| Animals | 20 | 2023 | 15081 | 0.430 |
Why?
|
| Biomedical Research | 1 | 2017 | 400 | 0.430 |
Why?
|
| Female | 18 | 2023 | 20969 | 0.420 |
Why?
|
| Hair Cells, Auditory | 3 | 2020 | 10 | 0.380 |
Why?
|
| Humans | 24 | 2023 | 37093 | 0.320 |
Why?
|
| Leadership | 3 | 2023 | 76 | 0.310 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 420 | 0.310 |
Why?
|
| Mice | 7 | 2023 | 5913 | 0.290 |
Why?
|
| Los Angeles | 3 | 2022 | 380 | 0.280 |
Why?
|
| Young Adult | 5 | 2022 | 4268 | 0.240 |
Why?
|
| Cochlea | 2 | 2022 | 3 | 0.240 |
Why?
|
| Vestibular Diseases | 1 | 2023 | 3 | 0.240 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 8 | 0.240 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 14 | 0.230 |
Why?
|
| Abnormalities, Multiple | 1 | 2023 | 36 | 0.230 |
Why?
|
| Siblings | 1 | 2023 | 18 | 0.230 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2022 | 164 | 0.230 |
Why?
|
| Face | 1 | 2023 | 51 | 0.220 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 242 | 0.220 |
Why?
|
| Food | 1 | 2023 | 100 | 0.210 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 79 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 94 | 0.210 |
Why?
|
| Echolocation | 1 | 2021 | 1 | 0.200 |
Why?
|
| Sexual Partners | 2 | 2022 | 314 | 0.200 |
Why?
|
| Chiroptera | 1 | 2021 | 20 | 0.200 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 64 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 94 | 0.200 |
Why?
|
| Physicians | 1 | 2023 | 163 | 0.200 |
Why?
|
| Psychoacoustics | 3 | 2020 | 5 | 0.200 |
Why?
|
| Education, Medical | 1 | 2022 | 104 | 0.200 |
Why?
|
| Homosexuality, Male | 3 | 2023 | 458 | 0.200 |
Why?
|
| Animal Communication | 1 | 2021 | 4 | 0.200 |
Why?
|
| Aging | 3 | 2022 | 664 | 0.200 |
Why?
|
| Mole Rats | 1 | 2020 | 5 | 0.190 |
Why?
|
| Fatty Liver | 1 | 2021 | 64 | 0.190 |
Why?
|
| Adult | 7 | 2022 | 11712 | 0.190 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 10 | 0.190 |
Why?
|
| Sex Characteristics | 2 | 2020 | 230 | 0.180 |
Why?
|
| United States | 5 | 2023 | 4223 | 0.180 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 1371 | 0.180 |
Why?
|
| Species Specificity | 3 | 2015 | 245 | 0.180 |
Why?
|
| Curcumin | 1 | 2020 | 74 | 0.180 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 107 | 0.180 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 174 | 0.180 |
Why?
|
| Sexual Behavior | 2 | 2022 | 609 | 0.180 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 109 | 0.170 |
Why?
|
| Neurons | 3 | 2017 | 1175 | 0.170 |
Why?
|
| Mexican Americans | 1 | 2021 | 189 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 197 | 0.170 |
Why?
|
| Thalamus | 1 | 2018 | 30 | 0.160 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 268 | 0.160 |
Why?
|
| Visual Perception | 1 | 2018 | 67 | 0.160 |
Why?
|
| Visual Cortex | 1 | 2018 | 60 | 0.160 |
Why?
|
| Long-Term Potentiation | 1 | 2018 | 102 | 0.160 |
Why?
|
| Middle Aged | 6 | 2023 | 10129 | 0.160 |
Why?
|
| Inferior Colliculi | 1 | 2017 | 3 | 0.150 |
Why?
|
| Minority Groups | 1 | 2022 | 596 | 0.150 |
Why?
|
| Exercise | 1 | 2023 | 613 | 0.150 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 33 | 0.150 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2017 | 12 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 864 | 0.150 |
Why?
|
| Catecholamines | 1 | 2017 | 44 | 0.150 |
Why?
|
| Cornea | 2 | 1988 | 58 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 2721 | 0.140 |
Why?
|
| Reaction Time | 2 | 2014 | 143 | 0.140 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 48 | 0.140 |
Why?
|
| Collagen | 2 | 1988 | 172 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 730 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2021 | 642 | 0.130 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 31 | 0.120 |
Why?
|
| Tympanic Membrane | 1 | 2014 | 1 | 0.120 |
Why?
|
| Sound Localization | 1 | 2014 | 4 | 0.120 |
Why?
|
| Electrophysiology | 1 | 2014 | 136 | 0.120 |
Why?
|
| Aged | 3 | 2023 | 6741 | 0.110 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 20 | 0.110 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 64 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 803 | 0.110 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2013 | 22 | 0.110 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 82 | 0.110 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 55 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2014 | 550 | 0.100 |
Why?
|
| Educational Status | 2 | 2023 | 313 | 0.100 |
Why?
|
| Models, Biological | 1 | 2014 | 677 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 481 | 0.090 |
Why?
|
| Research Design | 2 | 2023 | 313 | 0.080 |
Why?
|
| Keratoconus | 1 | 1988 | 16 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 125 | 0.070 |
Why?
|
| Lung | 2 | 2021 | 446 | 0.060 |
Why?
|
| Child | 2 | 2023 | 3131 | 0.060 |
Why?
|
| Causality | 1 | 2023 | 44 | 0.060 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 12 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 51 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 208 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2022 | 66 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 98 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 94 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 112 | 0.050 |
Why?
|
| Eating | 1 | 2023 | 166 | 0.050 |
Why?
|
| Benzeneacetamides | 2 | 2013 | 6 | 0.050 |
Why?
|
| Adolescent | 3 | 2022 | 5363 | 0.050 |
Why?
|
| Fentanyl | 2 | 2013 | 9 | 0.050 |
Why?
|
| Pyrrolidines | 2 | 2013 | 29 | 0.050 |
Why?
|
| Viral Load | 1 | 2022 | 312 | 0.050 |
Why?
|
| Africa | 1 | 2020 | 76 | 0.050 |
Why?
|
| Sirolimus | 1 | 2020 | 60 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 142 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2020 | 54 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2023 | 484 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 132 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 455 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 78 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 922 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 156 | 0.040 |
Why?
|
| Sensory Deprivation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2018 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 269 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2020 | 161 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 997 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 79 | 0.040 |
Why?
|
| Interneurons | 1 | 2018 | 56 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 601 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 578 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 137 | 0.040 |
Why?
|
| Auditory Pathways | 1 | 2017 | 8 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2017 | 53 | 0.040 |
Why?
|
| Methylation | 1 | 2017 | 113 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 1988 | 105 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1455 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 712 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2017 | 128 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 231 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 426 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 807 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1198 | 0.030 |
Why?
|
| Tubocurarine | 1 | 2014 | 3 | 0.030 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2014 | 3 | 0.030 |
Why?
|
| Immobilization | 1 | 2014 | 9 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 50 | 0.030 |
Why?
|
| Vibration | 1 | 2014 | 23 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 33 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 2231 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 43 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1609 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 2013 | 20 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2013 | 24 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 62 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 136 | 0.030 |
Why?
|
| Wakefulness | 1 | 2013 | 21 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 324 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 3562 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2013 | 78 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2013 | 150 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2020 | 1908 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 935 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 418 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 360 | 0.020 |
Why?
|
| Sulfur | 1 | 1989 | 18 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 14 | 0.020 |
Why?
|
| Self Administration | 1 | 2008 | 42 | 0.020 |
Why?
|
| Spironolactone | 1 | 1989 | 39 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2008 | 73 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2008 | 128 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 141 | 0.020 |
Why?
|
| Phenazines | 1 | 1988 | 3 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1988 | 50 | 0.020 |
Why?
|
| Azo Compounds | 1 | 1988 | 20 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 128 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 171 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 583 | 0.020 |
Why?
|
| Fixatives | 1 | 1986 | 7 | 0.020 |
Why?
|
| Corneal Diseases | 1 | 1986 | 9 | 0.020 |
Why?
|
| Reference Values | 1 | 1986 | 212 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1039 | 0.020 |
Why?
|
| Half-Life | 1 | 1989 | 54 | 0.010 |
Why?
|
| Biotransformation | 1 | 1989 | 67 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 421 | 0.000 |
Why?
|